BioMarin Pharmaceutical Inc.
DE ˙ DB ˙ US09061G1013
45,69 € ↓ -1,20 (-2,56%)
2026-06-03
AKTIENPREIS
SecurityDE:BM8 / BioMarin Pharmaceutical Inc.
InstitutionOssiam
Latest Disclosed Ownership21,829 shares
Latest Disclosed Value $ 1,233,120
Ossiam reports 87.12% increase in ownership of BM8 / BioMarin Pharmaceutical Inc.

On May 14, 2026 - Ossiam filed a 13F-HR form disclosing ownership of 21,829 shares of BioMarin Pharmaceutical Inc. (DE:BM8) valued at $1,047,355 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 11,666 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 87.12% during the quarter. The current value of the position is $997,367 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 21,829 10,163 87.12 1,233 77.92 0.0217
2026-02-13 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 11,666 -5,791 -33.17 693 -26.67 0.0138
2025-11-14 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 17,457 17,249 8,292.79 945 8,490.91 0.0122
2025-08-13 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 208 0 0.00 11 -21.43 0.0001
2025-05-14 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 208 -268 -56.30 15 -54.84 0.0002
2025-02-13 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 476 -2,369 -83.27 31 -84.42 0.0005
2024-11-13 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,845 -121 -4.08 200 -18.44 0.0039
2024-08-13 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,966 5 0.17 244 -5.43 0.0046
2024-05-13 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,961 -1,704 -36.53 259 -42.54 0.0045
2024-02-13 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,665 1,946 71.57 450 87.08 0.0072
2023-11-14 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,719 -52 -1.88 241 0.00 0.0043
2023-08-11 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,771 1,287 86.73 240 66.67 0.0043
2023-05-12 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,484 -5,597 -79.04 144 -80.33 0.0030
2023-02-13 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 7,081 2,620 58.73 733 93.65 0.0190
2022-11-14 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,461 -1,302 -22.59 378 -20.92 0.0109
2022-08-12 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 5,763 1,559 37.08 478 47.53 0.0144
2022-05-13 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,204 1,866 79.81 324 56.52 0.0085
2022-02-14 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,338 -719 -23.52 207 -12.29 0.0054
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,057 0 0.00 236 0.43 0.0067
2021-08-13 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 3,057 1,588 108.10 235 111.71 0.0064
2021-05-17 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,469 726 97.71 111 70.77 0.0035
2021-02-12 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 743 624 524.37 65 622.22 0.0023
2020-11-12 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 119 -2,016 -94.43 9 -96.58 0.0004
2020-08-13 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,135 -9,493 -81.64 263 -73.25 0.0168
2020-05-14 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 11,628 9,780 529.22 983 530.13 0.0669
2020-02-14 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,848 1,626 732.43 156 940.00 0.0119
2019-11-13 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 222 -556 -71.47 15 -77.61 0.0010
2019-08-13 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 778 778 67 0.0052
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.